These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 29164956)

  • 1. Have we successfully implemented CYP2D6 genotyping in psychiatry?
    de Leon J
    Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1201-1203. PubMed ID: 29164956
    [No Abstract]   [Full Text] [Related]  

  • 2. Incorporating pharmacogenetics into clinical practice: reality of a new tool in psychiatry. The context of genetic testing in clinical psychiatric practice.
    Mrazek DA
    CNS Spectr; 2006 Mar; 11(3 Suppl 3):3-4. PubMed ID: 17760222
    [No Abstract]   [Full Text] [Related]  

  • 3. Implementation of CYP2D6 genotyping in psychiatry.
    Loovers HM; van der Weide J
    Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1065-77. PubMed ID: 19572825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical significance of pharmacogenetics in psychiatry].
    Skrętkowicz J; Barańska M; Rychlik-Sych M
    Wiad Lek; 2013; 66(2 Pt 2):185-91. PubMed ID: 25775815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytochrome P450 2D6 genotyping: potential role in improving treatment outcomes in psychiatric disorders.
    Kirchheiner J; Rodriguez-Antona C
    CNS Drugs; 2009; 23(3):181-91. PubMed ID: 19320528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is pharmacogenetic CYP2D6 testing useful?
    Vetti HH; Molven A; Eliassen AK; Steen VM
    Tidsskr Nor Laegeforen; 2010 Nov; 130(22):2224-8. PubMed ID: 21109842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Role of genetics in psychiatric treatment].
    Hamdani N; Gorwood P
    Presse Med; 2008 May; 37(5 Pt 2):902-11. PubMed ID: 18356009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incorporating pharmacogenetics into clinical practice: reality of a new tool in psychiatry. Current issues in clinical implementation.
    de Leon J
    CNS Spectr; 2006 Mar; 11(3 Suppl 3):8-12. PubMed ID: 17760224
    [No Abstract]   [Full Text] [Related]  

  • 9. Personalized medicine in psychiatry: new technologies and approaches.
    Costa e Silva JA
    Metabolism; 2013 Jan; 62 Suppl 1():S40-4. PubMed ID: 23018148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies.
    Rodríguez-Antona C; Gurwitz D; de Leon J; Llerena A; Kirchheiner J; de Mesa EG; Ibarreta D
    Pharmacogenomics; 2009 Apr; 10(4):685-99. PubMed ID: 19374522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapeutic monitoring of psychotropic drugs and pharmacogenetic tests in psychiatry].
    Voirol P; Eap CB; Baumann P
    Rev Med Suisse Romande; 2000 Feb; 120(2):99-104. PubMed ID: 10748694
    [No Abstract]   [Full Text] [Related]  

  • 12. Personalized pharmacotherapy in psychiatry.
    Filaković P; Petek A
    Psychiatr Danub; 2009 Sep; 21(3):341-6. PubMed ID: 19794353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenomics in psychiatry: from therapeutic drug monitoring to genomic medicine.
    Crettol S; de Leon J; Hiemke C; Eap CB
    Clin Pharmacol Ther; 2014 Mar; 95(3):254-7. PubMed ID: 24196844
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical applications of CYP genotyping in psychiatry.
    Spina E; de Leon J
    J Neural Transm (Vienna); 2015 Jan; 122(1):5-28. PubMed ID: 25200585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychotropic drugs and CYP2D6 in late-life psychiatric and neurological disorders. What do we know?
    Seripa D; Lozupone M; Stella E; Paroni G; Bisceglia P; La Montagna M; D'onofrio G; Gravina C; Urbano M; Priore MG; Lamanna A; Daniele A; Bellomo A; Logroscino G; Greco A; Panza F
    Expert Opin Drug Saf; 2017 Dec; 16(12):1373-1385. PubMed ID: 29025271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics and drug therapy in psychiatry--the role of the CYP2D6 polymorphism.
    Vandel P; Talon JM; Haffen E; Sechter D
    Curr Pharm Des; 2007; 13(2):241-50. PubMed ID: 17269931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do guidelines recommending pharmacogenetic testing of psychiatric patients affect treatment costs and the use of healthcare services?
    Herbild L; Bech M; Gyrd-Hansen D; Christensen M; Werge T; Nielsen KA
    Scand J Public Health; 2011 Mar; 39(2):147-55. PubMed ID: 21257648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity.
    Llerena A; Dorado P; Peñas-Lledó EM
    Pharmacogenomics; 2009 Jan; 10(1):17-28. PubMed ID: 19102711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphic drug metabolism (CYP2D6) and utilisation of psychotropic drugs in hospitalised psychiatric patients: a retrospective study.
    Tamminga WJ; Wemer J; Oosterhuis B; de Boer A; Vranckx S; Drenth BF; de Zeeuw RA; de Leij LF; Jonkman JH
    Eur J Clin Pharmacol; 2003 May; 59(1):57-64. PubMed ID: 12743673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP2D6 variation, behaviour and psychopathology: implications for pharmacogenomics-guided clinical trials.
    Peñas-Lledó EM; Llerena A
    Br J Clin Pharmacol; 2014 Apr; 77(4):673-83. PubMed ID: 24033670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.